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Summary: Smoking was examined in relation to Parkinson’s disease (PD) in a 
population-based study in northern Manhattan (New York City) because of its 
putative “protective effect.” Using a case-control design, information on 
smoking and associated behaviors was obtained in structured interviews after 
standard diagnostic evaluations in both cases and controls. The overall prev- 
alence of smoking in the population was 43.7%, decreasing to 37% after age 85. 
Smoking was most frequent in men, Blacks, and in both cases and controls 
using alcohol once per week or more. Cases had quit smoking more often than 
controls (87 vs. a%), and had smoked for significantly fewer years (31 vs. 41 
yrs; p < 0.05 for both). The age-at-onset for smokers with PD was similar to 
age-at-onset for nonsmokers with PD. The odds ratio (OR) for a history of 
smoking associated with PD was 1.1 (95% CI 0.7-1.8). No protective gradient 
was associated with heavier smoking patterns. However, the odds that patients 
with PD were still smoking at the time of the interview were significantly less 
than those for controls (OR = 0.2; 95% CI 0.1-0.5). These results do not 
support the hypothesis that smoking protects against PD; rather they strongly 
imply the converse, that PD reduces smoking. Key Words: Smoking- 
Parkinson’s disease. 
Several case-control studies (1-5) have indicated 
that patients with Parkinson’s disease (PD) are less 
likely to have smoked than their healthy peers, 
leading to the inference that smoking may protect 
against this disorder. However, it has also been pro- 
posed that cessation of smoking may be related to a 
change in personality or a so-called “premorbid at- 
titude” that may exist in patients who develop PD 
(6). Smoking is thought to reduce the risk of devel- 
oping PD by protecting the substantia nigra from 
potentially toxic effects of oxidative radicals pro- 
duced during the normal metabolism of dopamine 
(7,W 
There are at least three additional explanations 
for the negative association between smoking and 
PD: (a) recall bias, a methodologic problem com- 
mon to all case-control studies (9); (b) physical or 
mental limitations imposed by PD result in the ces- 
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sation of smoking (10); (c) differential mortality in 
which smokers with PD die earlier than nonsmokers 
(1 1,12). 
We examined data collected from patients with 
PD as well as a group of healthy elderly controls 
identified in a community-based study of age- 
related degenerative diseases in northern Manhat- 
tan (New York City). We postulated that a negative 
association between smoking and PD would imply 
that smoking might decrease the risk of developing 
this disease. We also posited that if the negative 
association was stronger for current rather than 
past smoking the presence of a degenerative disease 
might have led to cessation of smoking. 
METHODS 
Setting and Subjects 
Data were obtained from cases and controls par- 
ticipating in a study of degenerative disease in the 
elderly residing in the Washington Heights and In- 
wood communities of New York City during the 
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period of April 1, 1988 to December 31, 1990. We 
had developed a registry of cases of PD from all 
available sources of medical information: regional 
hospitals (including inpatient and outpatient ser- 
vices), private practitioners in the community, fed- 
eral and state health agencies, health maintenance 
organizations, and senior centers. Each reporting 
site was also used to identify controls. The primary 
inclusion criteria for cases and controls was resi- 
dence in the community for a period of at least 
5 years. Exclusion criteria for cases and controls 
in terms of comorbidity were identical. The refus- 
al rate for both cases and controls was <20% 
using this method, and did not differ significantly by 
site. 
Parkinson’s Disease 
Two hundred fifty-eight patients with parkinson- 
ism were identified in the community registry (13). 
After the diagnosis was confirmed by an experi- 
enced neurologist (RM, KM, or LJC), 217 cases 
satisfied clinical and research criteria for the idio- 
pathic form of PD (14-16). Sixty-seven (30.1%) 
were also found to be demented at the time of 
the examination, meeting additional research diag- 
nostic criteria for primary degenerative dementia 
(17). Patients with dementia were excluded from 
the main analyses because dementia in PD is a het- 
erogeneous disorder with no firmly established 
pathologic substrate, and because we wanted accu- 
racy in the subject’s smoking history. No other ex- 
clusion criteria were imposed. This left 150 non- 
demented cases. Onset of PD was determined by 
the examining physician in a semistructured inter- 
view, and it was defined as the approximate age at 
which the patient noted the onset of motor manifes- 
tations. 
Healthy Controls 
During the same period, 416 elderly persons, 
aged 65 and older, had been identified at the same 
registry sites as potential controls. Each individual 
was asked to participate in a community study of 
aging and health. As with the cases, all controls 
were examined for dementia and PD using methods 
developed for this community (18,19). All had a 
complete medical, neurologic, and psychiatric as- 
sessment which included structured interviews of 
current and past health, current function in daily 
activities, and a general physical, neurologic, and 
neuropsychologic examination. The first consecu- 
tive 180 subjects without evidence of dementia, an- 
other neurologic disease, or a major illness such as 
cancer or severe heart disease, after clinical exam- 
ination or neuropsychologic testing, also completed 
the risk factor interview. As with cases, we in- 
cluded subjects in this group with milder systemic 
illnesses such as hypertension, diabetes, and arthri- 
tis, so long as they were free of major neurologic or 
medical complications. None of the controls were 
spouses or caretakers of the patients. Because all 
cases and controls were from the same community 
it is conceivable that some were friends or neigh- 
bors, but we have no information suggesting this. 
Ethnic Group 
For ethnic group classification, we used the for- 
mat suggested by the 1990 United States Census 
Bureau (20). The 1990 census identified Hispanics 
as a cultural group, and reported this population as 
a proportion of the total. No independent counts 
were available. For this study, we used the catego- 
ries of Black, White, and Other to be consistent 
with the census data. 
Risk Factor Interview 
Patients with PD and the controls were inter- 
viewed directly using a structured risk factor ques- 
tionnaire. The interviews were given in English or 
Spanish according to the preference of the patient 
or the control. We assessed reliability by repeating 
the interview 12 months later with 23 patients and 
25 controls. 
For smoking there were three sets of questions. A 
trigger question asked whether or not the individual 
ever smoked at least one cigarette per day for a 
period of a year or more. If the answer was no, no 
further questions were asked; if yes, the individual 
was asked at what age smoking began, whether or 
not smoking continued, at what age smoking had 
stopped if no longer smoking, and how many ciga- 
rettes, on average, had been smoked or were still 
being smoked per day. We computed the total num- 
ber of pack-years for each person by multiplying the 
number of years smoked times the number (or frac- 
tion) of packages (20 cigarettes per package) 
smoked per day. 
The two other sets of smoking questions asked 
about cigar and pipe use. Both began with a trigger 
question asking whether or not the individual had 
ever smoked a cigar or pipe. If answered no, no 
further questions were asked; if yes, follow-up 
questions similar to those for cigarettes were asked 
but referred to the number of cigars or pipefuls 
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smoked daify. There were also three similar sets of 
questions concerning alcohol use and coffee con- 
sumption. 
Data Analysis 
The frequencies for each demographic variable 
(age, gender, education, and ethnic group), and for 
smoking and other covariates were compared in 
cases and controls using x2 analyses and Fisher's 
exact tests (21). 
Odds ratios were calculated to assess the relation 
of PD to smoking and other demographic variables. 
Both univariate and multivariate OR were esti- 
mated from logistic regression models. We exam- 
ined differences with respect to education and eth- 
nic group identity represented in the community. 
First, two continuous independent variables were 
used in the multivariate analyses for preliminary ex- 
amination, then they were dichotomized using a 
reasonable point near the median value because of 
their bimodal distribution in the cohort: cigarettes 
per day (S10 per day) and pack-years (830 years). 
We examined differences with respect to ethnic 
group identity. Odds ratios were adjusted for poten- 
tial confounders and effect modifiers by using logis- 
tic regression (22). 
Multivariate analysis of variance (23) was used to 
examine group differences in various characteris- 
tics while controlling for the effects of other factors 
such as age. 
RESULTS 
Demographics 
Table 1 compares cases and controls in terms of 
the demographic variables. There were significantly 
more men in the PD group than in the controls, and 
cases were significantly older than the controls (p < 
0.001). Cases also had significantly more formal ed- 
TABLE 1. Demographic characteristics 
Characteristics 
n 
Gender (% women) 
Age (SD) 
Education (SD) 





















Indicates significant dif€erence from controls, p < 0.001. 
TABLE 2. Prevalence of past or current smoking by 
age, gender, education, ethnic group, and alcohol use 
among cases and controls 
Characteristic 
Age group (years) 
65-74 
75-84 
















Total PD smokers Controls smokers 
(n = 150) (%) (n = 180) (%) 
44 21 (48%) 91 40(44%) 
56 25 (45%) 66 28 (42%) 
10 6 (60%) 17 4 (24%) 
75 18 (24%) 145 53 (37%) 
75 51 (68%)= 35 24(67%)" 
38 19 (50%) 71 28 (3%) 
55 23 (42%) 38 17 (45%) 
74 33 (45%) 54 27 (50%) 
19 13 (68%)" 59 32 (54%) 
97 43 (44%) 71 25 (35%) 
34 13 (38%) 50 20 (40%) 
39 32(82%)" 33 23 (70%0)" 
111 37 (33%) 145 53 (37%) 
~ ~~~~- 
' Significant difference from others in the group, p < 0.05. 
ucation and were more likely to be White (p < 
0.001). 
Smoking 
Table 2 indicates that the frequency of smoking 
(past and current) in all subjects (cases and con- 
trols) varied significantly by gender and alcohol use 
in both cases and controls. A history of smoking 
was more frequent among black patients, but smok- 
ing was similar among controls regardless of ethnic 
group (Table 2). The test-retest reliability (21) of 
the risk factor interview was in the good-to-excel- 
lent range for the questions regarding smoking (k = 
0.72). 
The majority of smokers among both cases and 
controls were cigarette smokers. Only seven pa- 
tients with PD and five controls restricted their 
smoking to cigars or a pipe. A few in each group 
smoked cigars or a pipe as well as cigarettes accord- 
ing to our definition. We did not perform separate 
analyses for those who use only cigars or pipes be- 
cause these were relatively infrequent as expo- 
sures. However, we did include cigar and pipe 
smokers in comparing smokers with nonsmokers, 
Table 3 indicates that, after adjusting for age dif- 
ferences, patients with PD had smoked for signif- 
cantly fewer years than controls. There were no 
significant differences between cases and controls 
in the average number of cigarettes per day or the 
total number of pack-years. Significantly more 
cases, than controls, had stopped smoking. 
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TABLE 3. Cigarette smoking characteristics: 




Years smoked (SD) 31.3 (17.5)" 41.3 (18.1) 
Cigarettedday (SD) 19.5 (16.2) 17.7 (16.9) 
Pack-years (SD)b 31.4 (26.2) 36.5 (39.2) 
Smokers who quit (%) 60 (87%) 49 (64%)a 
(means) 
a Denotes significant association, p < 0.01. 
'Pack-years was defined as the product of the number of 
years smoked times the number (or fraction) of packages (20 
cigarettes per package) smoked per day. 
Parkinson's Disease 
The frequency of a past history of smoking was 
similar among cases and controls (Table 4), whereas 
current smoking was increased among controls 
compared with cases. Dose response was not ob- 
served with regard to the number of cigarettes 
smoked per day or the number of pack-years. Re- 
sults in Table 2 indicate that the only potential con- 
founder to be considered is gender because al- 
though ethnic group and alcohol use were related to 
smoking they were not associated with PD specifi- 
cally. The OR adjusted for age and gender disclosed 
a trend toward a negative association between PD 
and smoking more than 30 pack-years only. When 
these analyses were repeated excluding current 
smokers, the point estimates increased toward 
unity. 
We examined the effects of alcohol use and eth- 
nic group identity on the association between smok- 
ing and PD. The combination of smoking and alco- 
hol was found to have a significant negative associ- 
ation when adjusted for age and gender (Table 5a). 
We reanalyzed this relation excluding current 
smokers among cases and controls and the point 
estimate was 0.9 (0.4-1.8), suggesting no associa- 
tion, The relation between ethnic group identity and 
smoking among PD cases and controls indicated a 
strong correlation with ethnic group, but little 
change with the addition of smoking (Table 5b). For 
patients with PD, the age-at-onset of symptoms in 
smokers and nonsmokers was nearly identical 164.2 
(216.1) smokers vs. 64.5 (&12.4) nonsmokers;p = 
0.881. 
Although we determined our sample size based 
on the known frequency of smoking in the commu- 
nity and with the objective of observing an OR of 
0.5 or less, we had at least 80% power to detect a 
previously reported OR of 0.7 for PD (24). For the 
adjusted analyses our power was less. The smallest 
detectable OR we could have observed in our anal- 
yses adjusted for age and gender was estimated to 
be 0.5 (25). In PD, many of the detailed analyses of 
smoking included risk factors that were relatively 
infrequent. A post hoc estimation of the minimal 
detectable OR that we could have expected for the 
infrequent exposures such as more than 30 pack- 
years, present in only 15.4% of the study popula- 
tion, was approximately 0.4 (25). 
DISCUSSION 
The results of this investigation do not support 
the hypothesis that smoking prevents PD. Cases 
with PD were as likely as controls to have smoked 
and there was no difference in the average number 
of cigarettes used per day or total number of pack- 
years smoked. In PD, current smoking was signifi- 
cantly less frequent than in controls, even after ad- 
justment for covariates such as age and gender. A 































Odds ratios with 95% CI 
Unadjusted age and gender current smokers 
1 .O reference 1 .O reference 1 .O reference 
I .  1 (0.7-1.8) 0.B (0.4-1.5) - 
1.6 (1.0-2.5) 0.9 (0.5-1.6) 1.0 (0.61.7) 
0.4 (0.2-1.0) 0 2 (0. r4.s) - 
Adjusted for Excluding 
1 . 1  (0.6-1.9) 0.7 (0 .4  1.5) 1 .O (0.5-1.9) 
1.2 (0.7-2.1) 0.6 (0.3-1.2) 0.9 (0.5-1.8) 
1.3 (0.7-2.2) 0.8 (0.4-1.5) 1 . 1  (0.5-2.4) 
1.2 (0.7-2.3) 0.6 (0.3-1 2) 1.0 (0.5-2.0) 
~ ~~ 
Note: In order to calculate pack-years we needed to know when patients began and stopped smok- 
ing. This information could not be established in 10 PD smokers and 10 control smokers. 
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a. Smoking and alcohol use 
Status Cases Controls 
Neither 62 83 
Alcohol only 19 19 
Smoking only 27 36 
Both 42 40 
b. Smoking and ethnic group 
White nonsmokers 54 46 
Other + nonsmokers 27 57 
Other + smokers 26 52 
White smokers 43 25 
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Odds ratios with 95% CI 
Adjusted for 
Unadjusted age and gender 
1 .O reference 1 .O reference 
1.3 (0.7-2.7) 0.8 (0.41.5) 
1.0 (0.5-1.9) 0.9 (0.4-2.0) 
1.4 (0.g2.4) 0.5 (0.3-1 .O) 
1 .O reference 1 .O reference 
0.4 (0.2-0.8) 0.3 (0.1-0.5) 
0.4 (0.24.8) 0.4 (0.2-0.7) 
1.5 (0.8-2.6) 0.8 (0.41.7) 
TABLE 5 .  Effects of alcohol use and ethnic group on the association between smoking 
and Parkinson’s disease 
Note: Other + in (b) refers to Black and Other nonwhite ethnic groups combined, 
negative association between PD and the combina- 
tion of alcohol use and smoking was suggested after 
adjustment for age and gender, but this disappeared 
once current smokers were excluded from the anal- 
ysis. This suggests that current, not previous, 
smoking patterns were changed in cases compared 
with controls. Whites were more likely to have PD 
regardless of smoking habits. PD has been found to 
occur less frequently among Blacks than in other 
ethnic groups in some, but not all studies (26-28). 
Although the results of several case-control stud- 
ies (1-6) have suggested that patients with PD are 
less likely to have smoked than their healthy peers, 
the association remains an inconsistent one. The 
diagnosis of PD has often not been verified, partic- 
ularly in mortality studies, allowing for nondiffer- 
ential misclassification (9). No study has found a 
dose response indicating greater protection with 
moderate to heavy smoking. Stern et al. (5) found 
the OR associated with PD to be 0.5, adjusting for a 
history of head injury and rural residence. How- 
ever, they did not adjust for gender or age in their 
analysis, and controls were either “peer nomi- 
nated” or other people attending the clinic. Thus, 
their results are difficult to interpret. 
Rajput and colleagues (24) reported the onset of 
PD to be earlier in smokers than nonsmokers, but 
they found no relation between smoking and PD 
[OR = 0.7; 95% CI 0.4-1.21. However, Sasco and 
Paffenbarger (4) found that patients with PD were 
less likely to continue smoking, as did we. These 
studies imply that personality changes or physical 
limitations caused by PD may have altered smoking 
habits (29). Moreover, we found that significantly 
more patients than controls had quit smoking, sug- 
gesting that the presence of PD might have affected 
smoking behavior. 
The purported decreased risk of PD associated 
with smoking might be biased in the case-control 
design simply because of a more “rapidly fatal 
course” for patients with PD who continued to 
smoke (30). Ebmeier et al. (I 1) reported that a his- 
tory of smoking was associated with more deaths 
among patients with PD than among controls over a 
3.5-year period. This would result in decreased sur- 
vival for smokers with PD, leaving them under rep- 
resented in case-control studies. 
As in any case-control study, the potential for 
recall bias existed in our study. The effect would 
lead to misclassification of exposure and a trend 
toward protection, but we have no evidence to sup- 
port that misclassification occurred. Selective non- 
participation based on the exposure of smoking 
could have influenced our results, but another study 
(31) in this community found a similar frequency of 
smoking. Moreover, nonparticipation would have 
had to have been different for cases and controls to 
affect our results. We do not have information on 
smoking from individuals who have not participated 
in studies based in the Washington Heights area. 
Our study offers little to support a protective ef- 
fect of smoking on PD. However, the data from this 
study indicate that smoking most likely decreases 
as a consequence of PD. Whether smoking cessa- 
tion was due to changes in personality, addictive 
behavior, or other disease-related factors remains 
to be determined. 
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